Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis

Abstract

ObjectiveGlucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes mellitus, show promise in promoting weight loss and improving heart health in obese individuals without diabetes. Our goal was to examine existing research for conclusive evidence on various types of GLP-1 RAs for weight loss and cardiometabolic benefits in obesity without diabetes. MethodsWe conducted an electronic search on PubMed, Scopus, and Cochrane Central using keywords, such as “GLP-1 RA,” “obesity,” and “weight loss.” We considered all available global GLP-1 RAs for inclusion. Our analysis focused on weight loss, blood pressure (BP) changes (systolic and diastolic BPs), and lipid profile effects (high-density lipoprotein, low-density lipoprotein, total cholesterol, and triacylglycerol). We used a random-effects meta-analysis with the standardized mean difference (SMD), mean difference (MD), odds ratio, and relative risk to present the results. ResultsOur search yielded a total of 7535 articles. We included 15 trials in our study. GLP-1 RAs led to significant weight loss (MD, −8.77 kg; P <.01) in obese individuals. GLP-1 RAs also improved the systolic BP (MD, −4.13 mm Hg; P <.01), diastolic BP (MD, −1.39 mm Hg; P <.01), and lipid profiles, including improved levels of triacylglycerol (SMD, −0.99 mg/dL; P <.01), total cholesterol (SMD, −0.73 mg/dL; P <.01), very low-density lipoprotein (SMD, −1.11 mg/dL; P <.01), and low-density lipoprotein (SMD, −0.27 mg/dL; P <.01), and significantly increased high-density lipoprotein levels (SMD, 0.11 mg/dL; P <.01). However, GLP-1 RAs were associated with an increased risk of gastrointestinal adverse events. ConclusionGLP-1 RAs were found to be beneficial for not only weight loss but also reduction in risk factors for cardiovascular disease such as BP and lipid profile. Consistent beneficial results were observed across the various subtypes of GLP-1 RAs.